Recce Pharmaceuticals Receives A$6.21 Million from Research and Development (R&D) Rebate Payments

Posted: January 29, 2023 at 1:02 am

SYDNEY, Australia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce a total research and development (R&D) cash receipt of A$6,219,241.

See the rest here:
Recce Pharmaceuticals Receives A$6.21 Million from Research and Development (R&D) Rebate Payments

Related Posts